Home
User Guide
What's in a MalaCard Search Guide Our Sources
Analysis Tools
GeneCards GeneAnalytics GeneAlaCart PathCards VarElect TGex
News and Views Disease Lists/Categories
About
About MalaCards Our Publications Academic Licensing Weizmann Institute LifeMap Discovery® Terms of Use MalaCards Team
MCID: OVR034
MIFTS: 39

Ovarian Clear Cell Adenocarcinoma

Categories: Cancer diseases, Endocrine diseases, Reproductive diseases
Genes Tissues Related diseases Publications Pathways Drugs
Sources

Aliases & Classifications for Ovarian Clear Cell Adenocarcinoma

About this section

MalaCards integrated aliases for Ovarian Clear Cell Adenocarcinoma:

Name: Ovarian Clear Cell Adenocarcinoma 12 15 73

Classifications:

MalaCards categories:
Global: Cancer diseases
Anatomical: Endocrine diseases Reproductive diseases
See all MalaCards categories (disease lists)


External Ids:

Disease Ontology 12 DOID:5304
NCIt 50 C40078
UMLS 73 C1518693
Sources

Summaries for Ovarian Clear Cell Adenocarcinoma

About this section
MalaCards based summary : Ovarian Clear Cell Adenocarcinoma is related to clear cell adenocarcinoma and clear cell adenocarcinoma of the ovary. An important gene associated with Ovarian Clear Cell Adenocarcinoma is ARID1A (AT-Rich Interaction Domain 1A), and among its related pathways/superpathways are Pathways in cancer and Kaposi's sarcoma-associated herpesvirus infection. The drugs Carboplatin and Paclitaxel have been mentioned in the context of this disorder. Affiliated tissues include endothelial, ovary and skin, and related phenotypes are cardiovascular system and endocrine/exocrine gland

Sources

Related Diseases for Ovarian Clear Cell Adenocarcinoma

About this section

Diseases related to Ovarian Clear Cell Adenocarcinoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show all 29)
# Related Disease Score Top Affiliating Genes
1 clear cell adenocarcinoma 31.1 ARID1A HNF1B SMAD3
2 clear cell adenocarcinoma of the ovary 11.8
3 adenocarcinoma 10.8
4 nephrogenic systemic fibrosis 10.4 PIK3CA SMAD3
5 parotid gland cancer 10.4 ESR2 PIK3CA
6 ectrodactyly, ectodermal dysplasia, and cleft lip/palate syndrome 3 10.4 ARID1A PIK3CA
7 uterine body mixed cancer 10.3 ARID1A ESR2
8 serous cystadenocarcinoma 10.2 ESR2 PIK3CA
9 endometriosis 10.2
10 urinary tract obstruction 10.2 PIK3CA SMAD3
11 hypoxia 10.1
12 cystadenocarcinoma 10.0 ESR2 PIK3CA
13 dermatosis papulosa nigra 9.9 MTOR PIK3CA
14 ovarian clear cell carcinoma 9.9 ARID1A HNF1B PIK3CA
15 pancreatic neuroendocrine tumor 9.9 MTOR PIK3CA
16 ovarian cancer 1 9.9 ARID1A HNF1B PIK3CA
17 malignant ovarian surface epithelial-stromal neoplasm 9.9 ARID1A HNF1B PIK3CA
18 ovary epithelial cancer 9.9 ARID1A HNF1B PIK3CA
19 hemimegalencephaly 9.9 MTOR PIK3CA
20 endometriosis of ovary 9.9 ARID1A ESR2 HNF1B
21 renal cell carcinoma, nonpapillary 9.9
22 aging 9.9
23 vaginitis 9.9
24 mucinous adenocarcinoma 9.9
25 keratosis, seborrheic 9.8 MTOR PIK3CA
26 estrogen-receptor positive breast cancer 9.6 MTOR PIK3CA
27 clear cell adenofibroma 9.5 ARID1A MTOR PIK3CA
28 megalencephaly 9.2 MTOR PIK3CA
29 pancreatic cancer 8.8 MTOR PIK3CA SMAD3 WT1-AS

Graphical network of the top 20 diseases related to Ovarian Clear Cell Adenocarcinoma:



Diseases related to Ovarian Clear Cell Adenocarcinoma
Sources

Symptoms & Phenotypes for Ovarian Clear Cell Adenocarcinoma

About this section

MGI Mouse Phenotypes related to Ovarian Clear Cell Adenocarcinoma:

46
# Description MGI Source Accession Score Top Affiliating Genes
1 cardiovascular system MP:0005385 9.63 ARID1A ESR2 MTOR PIK3CA SMAD3 STMN1
2 endocrine/exocrine gland MP:0005379 9.43 ARID1A ESR2 HNF1B MTOR PIK3CA SMAD3
3 muscle MP:0005369 9.1 ARID1A ESR2 HNF1B MTOR PIK3CA STMN1
Sources

Drugs & Therapeutics for Ovarian Clear Cell Adenocarcinoma

About this section

Drugs for Ovarian Clear Cell Adenocarcinoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show all 49)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Carboplatin Approved Phase 3,Phase 1,Phase 2 41575-94-4 10339178 498142 38904
2
Paclitaxel Approved, Vet_approved Phase 3,Phase 2,Phase 1 33069-62-4 36314
3
Bevacizumab Approved, Investigational Phase 3,Phase 2,Phase 1 216974-75-3
4
Gemcitabine Approved Phase 3 95058-81-4 60750
5
Doxorubicin Approved, Investigational Phase 2, Phase 3,Phase 3 23214-92-8 31703
6
Olaparib Approved Phase 3,Phase 2 763113-22-0 23725625
7
Topotecan Approved, Investigational Phase 2, Phase 3 119413-54-6, 123948-87-8 60700
8
Glutamic Acid Approved, Nutraceutical Phase 3 56-86-0 33032
9
Cediranib Investigational Phase 3,Phase 2 288383-20-0 9933475
10
Doxil Approved June 1999 Phase 2, Phase 3,Phase 3 31703
11
Maleic acid Experimental Phase 3,Phase 2 110-16-7 444266
12 Angiogenesis Inhibitors Phase 3,Phase 2,Phase 1
13 Angiogenesis Modulating Agents Phase 3,Phase 2,Phase 1
14 Mitogens Phase 3,Phase 2,Phase 1
15 Albumin-Bound Paclitaxel Phase 3,Phase 2,Phase 1
16 Endothelial Growth Factors Phase 3,Phase 2,Phase 1
17 Immunoglobulin G Phase 3,Phase 2,Phase 1
18 Antibodies Phase 3,Phase 2,Phase 1
19 Immunoglobulins Phase 3,Phase 2,Phase 1
20 Antibodies, Monoclonal Phase 3,Phase 2,Phase 1
21 Antimitotic Agents Phase 3,Phase 2,Phase 1
22 Antineoplastic Agents, Phytogenic Phase 3,Phase 2,Phase 1
23 Micronutrients Phase 3
24 Topoisomerase Inhibitors Phase 2, Phase 3,Phase 3
25 Trace Elements Phase 3
26 Anti-Bacterial Agents Phase 2, Phase 3,Phase 3
27 Antibiotics, Antitubercular Phase 2, Phase 3,Phase 3
28 Poly(ADP-ribose) Polymerase Inhibitors Phase 3,Phase 2,Phase 1
29 Immunosuppressive Agents Phase 3,Phase 2
30 Anti-Infective Agents Phase 3
31 Protein Kinase Inhibitors Phase 3,Phase 2
32 Antimetabolites Phase 3
33 Antiviral Agents Phase 3
34 Antimetabolites, Antineoplastic Phase 3
35 Carotenoids Phase 3
36 taxane Phase 3
37 topoisomerase I inhibitors Phase 2, Phase 3
38
Sunitinib Approved, Investigational Phase 2 341031-54-7, 557795-19-4 5329102
39
Cyclophosphamide Approved, Investigational Phase 2 50-18-0, 6055-19-2 2907
40
Iodine Approved, Investigational Phase 1, Phase 2 7553-56-2 807
41
Pembrolizumab Approved Phase 2 1374853-91-4
42
Xylometazoline Approved, Investigational Phase 2 526-36-3 5709
43 Alkylating Agents Phase 2
44 Antirheumatic Agents Phase 2
45 Antineoplastic Agents, Alkylating Phase 2
46 tyrosine Nutraceutical Phase 2
47
Bortezomib Approved, Investigational Phase 1 179324-69-7 387447 93860
48
Cisplatin Approved Phase 1 15663-27-1 84093 441203 2767
49
Veliparib Investigational Phase 1 912444-00-9 11960529

Interventional clinical trials:

(show all 18)
# Name Status NCT ID Phase Drugs
1 Carboplatin and Paclitaxel With or Without Bevacizumab in Treating Patients With Stage III or Stage IV Ovarian Epithelial, Primary Peritoneal, or Fallopian Tube Cancer Completed NCT00262847 Phase 3 Carboplatin;Paclitaxel
2 Pegylated Liposomal Doxorubicin Hydrochloride With Atezolizumab and/or Bevacizumab in Treating Patients With Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Recruiting NCT02839707 Phase 2, Phase 3 Atezolizumab;Pegylated Liposomal Doxorubicin Hydrochloride
3 Olaparib or Cediranib Maleate and Olaparib Compared With Standard Platinum-Based Chemotherapy in Treating Patients With Recurrent Platinum-Sensitive Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Recruiting NCT02446600 Phase 3 Carboplatin;Cediranib Maleate;Gemcitabine Hydrochloride;Olaparib;Paclitaxel;Pegylated Liposomal Doxorubicin Hydrochloride
4 Diet and Physical Activity Change or Usual Care in Improving Progression-Free Survival in Patients With Previously Treated Stage II, III, or IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Recruiting NCT00719303 Phase 3
5 Paclitaxel, Polyglutamate Paclitaxel, or Observation in Treating Patients With Stage III or Stage IV Ovarian Epithelial, Peritoneal Cancer, or Fallopian Tube Cancer Active, not recruiting NCT00108745 Phase 3 Paclitaxel;Paclitaxel Poliglumex
6 Cediranib Maleate and Olaparib or Standard Chemotherapy in Treating Patients With Recurrent Platinum-Resistant or -Refractory Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Suspended NCT02502266 Phase 2, Phase 3 Cediranib Maleate;Olaparib;Paclitaxel;Pegylated Liposomal Doxorubicin Hydrochloride;Topotecan Hydrochloride
7 Sunitinib® in Patients With Recurrent Ovarian Clear Cell Carcinoma Unknown status NCT01824615 Phase 2 Sunitinib
8 A Multicentre Phase II Trial of Durvalumab Versus Physician's Choice Chemotherapy in Recurrent Ovarian Clear Cell Adenocarcinomas Recruiting NCT03405454 Phase 2 durvalumab;standard chemotherapy
9 MV-NIS Infected Mesenchymal Stem Cells in Treating Patients With Recurrent Ovarian Cancer Recruiting NCT02068794 Phase 1, Phase 2
10 Pembrolizumab, Bevacizumab, and Cyclophosphamide in Treating Patients With Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Recruiting NCT02853318 Phase 2 Cyclophosphamide
11 Ruxolitinib Phosphate, Paclitaxel, and Carboplatin in Treating Patients With Stage III-IV Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Recruiting NCT02713386 Phase 1, Phase 2 Carboplatin;Paclitaxel;Ruxolitinib Phosphate
12 Sunitinib Malate in Treating Patients With Persistent or Recurrent Clear Cell Ovarian Cancer Active, not recruiting NCT00979992 Phase 2 Sunitinib Malate
13 Cabozantinib-S-Malate in Treating Patients With Recurrent or Progressive Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Active, not recruiting NCT02315430 Phase 2 Cabozantinib S-malate
14 Elesclomol Sodium and Paclitaxel in Treating Patients With Recurrent or Persistent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer Active, not recruiting NCT00888615 Phase 2 Elesclomol Sodium;Paclitaxel
15 Intraperitoneal Bortezomib and Carboplatin in Treating Patients With Persistent or Recurrent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer Completed NCT01074411 Phase 1 Bortezomib;Carboplatin
16 Carboplatin, Paclitaxel, Bevacizumab, and Veliparib in Treating Patients With Newly Diagnosed Stage II-IV Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cancer Active, not recruiting NCT00989651 Phase 1 Carboplatin;Cisplatin;Paclitaxel;Veliparib
17 Paclitaxel Albumin-Stabilized Nanoparticle Formulation and Bevacizumab in Treating Patients With Stage IV Melanoma That Cannot Be Removed by Surgery or Gynecological Cancers Suspended NCT02020707 Phase 1 Paclitaxel Albumin-Stabilized Nanoparticle Formulation
18 Ovarian Clear Cell Adenocarcinoma Review Completed NCT02129036

Search NIH Clinical Center for Ovarian Clear Cell Adenocarcinoma

Sources

Genetic Tests for Ovarian Clear Cell Adenocarcinoma

About this section
Sources

Anatomical Context for Ovarian Clear Cell Adenocarcinoma

About this section

MalaCards organs/tissues related to Ovarian Clear Cell Adenocarcinoma:

41
Endothelial, Ovary, Skin
Sources

Publications for Ovarian Clear Cell Adenocarcinoma

About this section

Articles related to Ovarian Clear Cell Adenocarcinoma:

(show top 50) (show all 88)
# Title Authors Year
1
Synchronous occurrence of primary right ovarian endometrioid adenocarcinoma and primary left ovarian clear cell adenocarcinoma: A case report. ( 29979406 )
2018
2
Alpha-fetoprotein-producing ovarian clear cell adenocarcinoma with fetal gut differentiation: a rare case report and literature review. ( 29933751 )
2018
3
Skin metastases in ovarian clear cell adenocarcinoma: a case report and a review of the literature. ( 29184869 )
2017
4
Vesical clear cell adenocarcinoma arising from endometriosis: A mullerian tumor, indistinguishable from ovarian clear cell adenocarcinoma. ( 27660815 )
2016
5
Somatic copy number alterations associated with Japanese or endometriosis in ovarian clear cell adenocarcinoma. ( 25658832 )
2015
6
Clinicopathological heterogeneity in ovarian clear cell adenocarcinoma: a study on individual therapy practice. ( 25398420 )
2014
7
Mass Spectrometric Analysis of the Phosphorylation Levels of the SWI/SNF Chromatin Remodeling/Tumor Suppressor Proteins ARID1A and Brg1 in Ovarian Clear Cell Adenocarcinoma Cell Lines. ( 25083560 )
2014
8
Non-diethylstilbestrol exposed vaginal clear cell adenocarcinoma has a common molecular profile with ovarian clear cell adenocarcinoma: A case report. ( 26082939 )
2014
9
Alpha-fetoprotein-producing ovarian clear cell adenocarcinoma simulating fetal gut in a postmenopausal woman. ( 24707459 )
2014
10
Defect of tropomyosin-related kinase B isotype expression in ovarian clear cell adenocarcinoma. ( 24815386 )
2014
11
Splenic metastasis of ovarian clear cell adenocarcinoma: A case report and review of the literature. ( 24669262 )
2014
12
Napsin A is a specific marker for ovarian clear cell adenocarcinoma. ( 24721826 )
2014
13
Antitumor activity and induction of TP53-dependent apoptosis toward ovarian clear cell adenocarcinoma by the dual PI3K/mTOR inhibitor DS-7423. ( 24504419 )
2014
14
Patterns of recurrence and role of pelvic radiotherapy in ovarian clear cell adenocarcinoma. ( 25275661 )
2014
15
Maximum standardized uptake value of fluorodeoxyglucose positron emission tomography/computed tomography is a prognostic factor in ovarian clear cell adenocarcinoma. ( 24987918 )
2014
16
Establishment and characterization of a novel ovarian clear cell adenocarcinoma cell line, TU-OC-1, with a mutation in the PIK3CA gene. ( 23430509 )
2013
17
Secretome-based identification of TFPI2, a novel serum biomarker for detection of ovarian clear cell adenocarcinoma. ( 23805888 )
2013
18
Expression of chromobox homolog 7 (CBX7) is associated with poor prognosis in ovarian clear cell adenocarcinoma via TRAIL-induced apoptotic pathway regulation. ( 24375438 )
2013
19
Alterations of hypoxia-induced factor signaling pathway due to mammalian target of rapamycin (mTOR) suppression in ovarian clear cell adenocarcinoma: in vivo and in vitro explorations for clinical trial. ( 23899586 )
2013
20
Integrative analysis of copy number alteration and gene expression profiling in ovarian clear cell adenocarcinoma. ( 23726144 )
2013
21
Met is the most frequently amplified gene in endometriosis-associated ovarian clear cell adenocarcinoma and correlates with worsened prognosis. ( 23469222 )
2013
22
Annexin A4 is involved in proliferation, chemo-resistance and migration and invasion in ovarian clear cell adenocarcinoma cells. ( 24244679 )
2013
23
A recurrence-predicting prognostic factor for patients with ovarian clear-cell adenocarcinoma at reproductive age. ( 24306200 )
2013
24
Stathmin Regulates Hypoxia-Inducible Factor-1I+ Expression through the Mammalian Target of Rapamycin Pathway in Ovarian Clear Cell Adenocarcinoma. ( 23819061 )
2013
25
ACTN4 gene amplification and actinin-4 protein overexpression drive tumour development and histological progression in a high-grade subset of ovarian clear-cell adenocarcinomas. ( 22348389 )
2012
26
Promoter methylation status of HIN-1 associated with outcomes of ovarian clear cell adenocarcinoma. ( 22871047 )
2012
27
[DNA damage response in ovarian clear cell adenocarcinoma]. ( 22812231 )
2012
28
PIK3CA mutations and loss of ARID1A protein expression are early events in the development of cystic ovarian clear cell adenocarcinoma. ( 22120431 )
2012
29
Two cases of ovarian clear cell adenocarcinoma producing estradiol. ( 22360511 )
2012
30
Histological grading of ovarian clear cell adenocarcinoma: proposal for a simple and reproducible grouping system based on tumor growth architecture. ( 22317866 )
2012
31
Aberrant expression of the mammalian target of rapamycin, hypoxia-inducible factor-1I+, and glucose transporter 1 in the development of ovarian clear-cell adenocarcinoma. ( 22498943 )
2012
32
Accumulative copy number increase of MET drives tumor development and histological progression in a subset of ovarian clear-cell adenocarcinomas. ( 21983935 )
2012
33
Analysis of mTOR inhibition-involved pathway in ovarian clear cell adenocarcinoma. ( 21614172 )
2011
34
Biological significance of plasminogen activator inhibitor-1 expression in ovarian clear cell adenocarcinoma. ( 22335020 )
2011
35
Validation of the histologic grading for ovarian clear cell adenocarcinoma: a retrospective multi-institutional study by the Japan Clear Cell Carcinoma Study Group. ( 21293288 )
2011
36
Gene amplification and protein overexpression of MET are common events in ovarian clear-cell adenocarcinoma: their roles in tumor progression and prognostication of the patient. ( 21478826 )
2011
37
Re-expression of estrogen receptor I^ inhibits the proliferation and migration of ovarian clear cell adenocarcinoma cells. ( 21874257 )
2011
38
Clear cell adenocarcinoma with a component of poorly differentiated histology: a poor prognostic subgroup of ovarian clear cell adenocarcinoma. ( 21804390 )
2011
39
PIK3CA mutation is an early event in the development of endometriosis-associated ovarian clear cell adenocarcinoma. ( 21735444 )
2011
40
IGFBP-1 is expressed specifically in ovarian clear cell adenocarcinoma. ( 21457161 )
2011
41
Wild-type p53 enhances annexin IV gene expression in ovarian clear cell adenocarcinoma. ( 21348943 )
2011
42
Promoter methylation of sFRP5 in patients with ovarian clear cell adenocarcinoma. ( 20486992 )
2010
43
Prognostic and predictive values of E-cadherin for patients of ovarian clear cell adenocarcinoma. ( 21119364 )
2010
44
Cumulative alterations of p27-related cell-cycle regulators in the development of endometriosis-associated ovarian clear cell adenocarcinoma. ( 20546339 )
2010
45
HOXA10 is overexpressed in human ovarian clear cell adenocarcinoma and correlates with poor survival. ( 20009888 )
2009
46
PTEN promoter methylation and LOH of 10q22-23 locus in PTEN expression of ovarian clear cell adenocarcinomas. ( 19007975 )
2009
47
Therapeutic strategy targeting the mTOR-HIF-1alpha-VEGF pathway in ovarian clear cell adenocarcinoma. ( 19121088 )
2009
48
Overexpression of class III beta-tubulin predicts good response to taxane-based chemotherapy in ovarian clear cell adenocarcinoma. ( 19228748 )
2009
49
Potential benefit of Sunitinib in recurrent and refractory ovarian clear cell adenocarcinoma. ( 18081793 )
2008
50
Glutathione peroxidase 3 is a candidate mechanism of anticancer drug resistance of ovarian clear cell adenocarcinoma. ( 19020706 )
2008
Sources

Variations for Ovarian Clear Cell Adenocarcinoma

About this section
Sources

Expression for Ovarian Clear Cell Adenocarcinoma

About this section
Search GEO for disease gene expression data for Ovarian Clear Cell Adenocarcinoma.
Sources

Pathways for Ovarian Clear Cell Adenocarcinoma

About this section

Pathways related to Ovarian Clear Cell Adenocarcinoma according to GeneCards Suite gene sharing:

(show all 17)
# Super pathways Score Top Affiliating Genes
1
Pathways in cancer 37
12.39 ESR2 MTOR PIK3CA SMAD3
2
Kaposi's sarcoma-associated herpesvirus infection 37
Show member pathways
 12.26 MTOR PIK3CA SMAD3
3
Development EGFR signaling pathway 22
Show member pathways
 12.22 MTOR PIK3CA SMAD3
4
MicroRNAs in cancer 37
12.2 MTOR PIK3CA STMN1
5
Prolactin Signaling Pathway 1 37
Show member pathways
 12.15 ESR2 MTOR PIK3CA
6
Cellular senescence (KEGG) 37
11.7 MTOR PIK3CA SMAD3
7
Gastric cancer 37
Show member pathways
 11.69 ARID1A ESR2 MTOR PIK3CA SMAD3
8
Transcription Androgen Receptor nuclear signaling 22
Show member pathways
 11.6 MTOR PIK3CA SMAD3
9
TGF-beta Signaling Pathways 65
11.31 ESR2 MTOR SMAD3
10
Thymic Stromal LymphoPoietin (TSLP) Signaling Pathway 1
11.21 MTOR PIK3CA
11
Type II diabetes mellitus 37 1
Show member pathways
 11.11 HNF1B MTOR PIK3CA
12
CXCR3-mediated signaling events 1
11.04 MTOR PIK3CA
13
Ovarian Infertility Genes 1
11 ESR2 SMAD3
14
Factors and pathways affecting insulin-like growth factor (IGF1)-Akt signaling 1
10.97 MTOR SMAD3
15
Extracellular vesicle-mediated signaling in recipient cells 1
10.93 MTOR SMAD3
16
PI3K-AKT-mTOR signaling pathway and therapeutic opportunities 1
10.91 MTOR PIK3CA
17
Plasma membrane estrogen receptor signaling 1
10.82 ESR2 PIK3CA
Sources

GO Terms for Ovarian Clear Cell Adenocarcinoma

About this section

Cellular components related to Ovarian Clear Cell Adenocarcinoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 phosphatidylinositol 3-kinase complex GO:0005942 8.62 MTOR PIK3CA

Biological processes related to Ovarian Clear Cell Adenocarcinoma according to GeneCards Suite gene sharing:

(show all 13)
# Name GO ID Score Top Affiliating Genes
1 negative regulation of transcription by RNA polymerase II GO:0000122 9.78 ARID1A ESR2 HNF1B SMAD3
2 positive regulation of transcription, DNA-templated GO:0045893 9.62 ARID1A ESR2 HNF1B SMAD3
3 positive regulation of stress fiber assembly GO:0051496 9.52 MTOR SMAD3
4 cardiac muscle contraction GO:0060048 9.51 MTOR PIK3CA
5 positive regulation of epithelial to mesenchymal transition GO:0010718 9.49 MTOR SMAD3
6 positive regulation of nitric oxide biosynthetic process GO:0045429 9.46 MTOR SMAD3
7 mitotic spindle organization GO:0007052 9.43 MAP4 STMN1
8 gastrulation GO:0007369 9.4 ARID1A SMAD3
9 endoderm development GO:0007492 9.37 HNF1B SMAD3
10 intracellular estrogen receptor signaling pathway GO:0030520 9.26 ARID1A ESR2
11 negative regulation of macroautophagy GO:0016242 9.16 MTOR PIK3CA
12 anoikis GO:0043276 8.96 MTOR PIK3CA
13 liver development GO:0001889 8.8 HNF1B PIK3CA SMAD3

Molecular functions related to Ovarian Clear Cell Adenocarcinoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 tubulin binding GO:0015631 9.16 MAP4 STMN1
2 binding GO:0005488 9.13 ARID1A MTOR PIK3CA
3 proximal promoter sequence-specific DNA binding GO:0000987 8.62 HNF1B SMAD3
Sources

Sources for Ovarian Clear Cell Adenocarcinoma

About this section
3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 SNOMED-CT via Orphanet
71 TGDB
72 Tocris
73 UMLS
74 UMLS via Orphanet
The MalaCards human disease database index: 1-9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
Content
Loading form....